Simon Khagi

1.8k total citations
28 papers, 325 citations indexed

About

Simon Khagi is a scholar working on Genetics, Oncology and Neurology. According to data from OpenAlex, Simon Khagi has authored 28 papers receiving a total of 325 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 12 papers in Oncology and 9 papers in Neurology. Recurrent topics in Simon Khagi's work include Glioma Diagnosis and Treatment (12 papers), Neuroblastoma Research and Treatments (8 papers) and Neuroendocrine Tumor Research Advances (4 papers). Simon Khagi is often cited by papers focused on Glioma Diagnosis and Treatment (12 papers), Neuroblastoma Research and Treatments (8 papers) and Neuroendocrine Tumor Research Advances (4 papers). Simon Khagi collaborates with scholars based in United States, Switzerland and China. Simon Khagi's co-authors include Shawn Hingtgen, David A. Reardon, Timothy F. Cloughesy, Stephen Bagley, Eudocia Q. Lee, Mostafa Yazdimamaghani, Gavin P. Dunn, Hongwei Du, Barbara Savoldo and Mustafa Khasraw and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Simon Khagi

23 papers receiving 322 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simon Khagi United States	9	113	110	101	72	67	28	325
Kok‐Siong Chen United States	12	109 1.0×	63 0.6×	211 2.1×	48 0.7×	85 1.3×	21	398
Frank Rommel Germany	9	77 0.7×	228 2.1×	98 1.0×	44 0.6×	82 1.2×	15	448
Adrian Kinzel United States	9	71 0.6×	192 1.7×	95 0.9×	136 1.9×	40 0.6×	35	401
Joseph Shan United States	10	83 0.7×	113 1.0×	104 1.0×	37 0.5×	137 2.0×	24	401
Malvina Prapa Italy	7	198 1.8×	76 0.7×	139 1.4×	83 1.2×	87 1.3×	10	350
Anandani Nellan United States	8	129 1.1×	96 0.9×	94 0.9×	48 0.7×	58 0.9×	18	265
Yuxia Meng France	5	106 0.9×	130 1.2×	88 0.9×	36 0.5×	227 3.4×	8	390
Leonel Ampie United States	10	206 1.8×	174 1.6×	122 1.2×	31 0.4×	227 3.4×	15	479
Diahnn Futalan United States	8	87 0.8×	128 1.2×	216 2.1×	35 0.5×	142 2.1×	11	439
Julie Sesen United States	8	69 0.6×	94 0.9×	250 2.5×	30 0.4×	36 0.5×	13	413

Countries citing papers authored by Simon Khagi

Since Specialization

Citations

This map shows the geographic impact of Simon Khagi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Khagi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Khagi more than expected).

Fields of papers citing papers by Simon Khagi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Khagi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Khagi. The network helps show where Simon Khagi may publish in the future.

Co-authorship network of co-authors of Simon Khagi

This figure shows the co-authorship network connecting the top 25 collaborators of Simon Khagi. A scholar is included among the top collaborators of Simon Khagi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon Khagi. Simon Khagi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Khagi, Simon, Jose Carrillo, David Park, et al.. (2025). CTIM-23. FIRST-IN-HUMAN IMMUNOTHERAPY TARGETING LYMPHOPENIA IN RECURRENT GLIOBLASTOMA MULTIFORM (GBM): NAI AND PD-L1 T-HANK PLUS BEVACIZUMAB WITH COMPLETE RESPONSE. Neuro-Oncology. 27(Supplement_5). v119–v119.

Khagi, Simon, et al.. (2024). Marine-Derived Therapeutics for the Management of Glioblastoma: A Case Series and Comprehensive Review of the Literature. SHILAP Revista de lepidopterología. 4(4). 369–380.

Khagi, Simon, Rupesh Kotecha, Na Tosha Gatson, et al.. (2024). Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma. The Oncologist. 30(2). 10 indexed citations

Dujmović, Irena, et al.. (2022). Paraneoplastic Optic Neuropathy in a Patient With Glioblastoma. Journal of Neuro-Ophthalmology. 44(1). e42–e44.

Reardon, David A., Steven Brem, Arati Desai, et al.. (2022). Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma.. Journal of Clinical Oncology. 40(16_suppl). 2004–2004. 19 indexed citations

Chen, Ashley, et al.. (2022). Response to Selpercatinib in a Patient With Recurrent Glioblastoma and RET Amplification. Journal of the National Comprehensive Cancer Network. 20(9). 966–971. 5 indexed citations

Bagley, Stephen, Shawn Kothari, Rifaquat Rahman, et al.. (2021). Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. Clinical Cancer Research. 28(4). 594–602. 104 indexed citations

Bomba, Hunter N., et al.. (2021). Use of FLOSEAL ® as a scaffold and its impact on induced neural stem cell phenotype, persistence, and efficacy. Bioengineering & Translational Medicine. 7(2). e10283–e10283. 7 indexed citations

Khagi, Simon, et al.. (2021). Next-generation sequencing reveals novel mutations in a collision tumor of glioblastoma and meningioma. CNS Oncology. 10(2). CNS70–CNS70. 6 indexed citations

10.

Tschernia, Nicholas & Simon Khagi. (2020). A Head Start: CAR-T Cell Therapy for Primary Malignant Brain Tumors. Current Treatment Options in Oncology. 21(9). 73–73. 1 indexed citations

11.

Buckley, Andrew, Juli R. Bagó, Simon Khagi, et al.. (2020). Generation and Profiling of Tumor-Homing Induced Neural Stem Cells from the Skin of Cancer Patients. Molecular Therapy. 28(7). 1614–1627. 15 indexed citations

12.

Bomba, Hunter N., Kevin Sheets, Simon Khagi, et al.. (2020). Personalized‐induced neural stem cell therapy: Generation, transplant, and safety in a large animal model. Bioengineering & Translational Medicine. 6(1). e10171–e10171. 13 indexed citations

13.

Satterlee, Andrew, Denise Dunn, Donald C. Lo, Simon Khagi, & Shawn Hingtgen. (2019). Tumoricidal stem cell therapy enables killing in novel hybrid models of heterogeneous glioblastoma. Neuro-Oncology. 21(12). 1552–1564. 16 indexed citations

14.

Kumar, Vaibhav, et al.. (2019). Hemophagocytic lymphohistiocytosis in a patient with glioblastoma: a case report. CNS Oncology. 8(4). CNS45–CNS45. 3 indexed citations

15.

Aiken, Robert, Clark Chen, Timothy F. Cloughesy, et al.. (2019). ATIM-33. INTERIM RESULTS OF A PHASE II MULTI-CENTER STUDY OF ONCOLYTIC ADENOVIRUS DNX-2401 WITH PEMBROLIZUMAB FOR RECURRENT GLIOBLASTOMA; CAPTIVE STUDY (KEYNOTE-192). Neuro-Oncology. 21(Supplement_6). vi8–vi9. 14 indexed citations

16.

Khagi, Simon, et al.. (2015). Abstract C201: Activity of the GlaxoSmithKline kinase inhibitor set on glioblastoma stem cells. Molecular Cancer Therapeutics. 14(12_Supplement_2). C201–C201. 1 indexed citations

17.

Khagi, Simon & M. W. Saif. (2014). Pancreatic neuroendocrine tumors. Current Opinion in Oncology. 27(1). 38–43. 7 indexed citations

18.

Khagi, Simon & Muhammad Wasif Saif. (2014). The Management of Gastroenteropancreatic Neuroendocrine Tumors with Somatostatin Analogues. PubMed. 15(4). 295–8. 1 indexed citations

19.

Khagi, Simon & Muhammad Wasif Saif. (2013). Neuroendocrine Tumors: Treatment Updates. PubMed. 14(4). 367–71. 2 indexed citations

20.

Patel, Forum, et al.. (2013). Pancreatic neuroendocrine tumor with ectopic adrenocorticotropin production: a case report and review of literature.. PubMed. 33(9). 4001–5. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact